Aviva’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13M | Buy |
77,269
+5,959
| +8% | +$884K | 0.02% | 502 |
|
|
2026
Q1 | $9.39M | Buy |
71,310
+887
| +1% | +$118K | 0.02% | 546 |
|
|
2025
Q4 | $9.99M | Buy |
70,423
+3,784
| +6% | +$548K | 0.02% | 544 |
|
|
2025
Q3 | $9.35M | Buy |
66,639
+4,893
| +8% | +$663K | 0.02% | 542 |
|
|
2025
Q2 | $7.76M | Buy |
61,746
+56,420
| +1,059% | +$6.47M | 0.02% | 560 |
|
|
2025
Q1 | $589K | Sell |
5,326
-56,592
| -91% | -$7.17M | ﹤0.01% | 727 |
|
|
2024
Q4 | $8.45M | Buy |
61,918
+37,826
| +157% | +$4.68M | 0.02% | 472 |
|
|
2024
Q3 | $2.78M | Sell |
24,092
-39,459
| -62% | -$5.41M | 0.01% | 522 |
|
|
2024
Q2 | $8.75M | Sell |
63,551
-1,411
| -2% | -$194K | 0.02% | 451 |
|
|
2024
Q1 | $8.96M | Buy |
64,962
+5,994
| +10% | +$819K | 0.03% | 461 |
|
|
2023
Q4 | $7.77M | Buy |
58,968
+44,182
| +299% | +$5.09M | 0.03% | 472 |
|
|
2023
Q3 | $1.66M | Buy |
+14,786
| New | +$1.56M | 0.01% | 642 |
|
|
2022
Q4 | – | Sell |
-18,036
| Closed | -$1.92M | – | 1020 |
|
|
2022
Q3 | $1.92M | Sell |
18,036
-37,919
| -68% | -$3.85M | 0.01% | 712 |
|
|
2022
Q2 | $5.45M | Buy |
+55,955
| New | +$5.16M | 0.03% | 567 |
|
|
2022
Q1 | – | Sell |
-21,787
| Closed | -$1.86M | – | 1088 |
|
|
2021
Q4 | $1.86M | Buy |
+21,787
| New | +$2M | 0.01% | 872 |
|
|
2021
Q2 | – | Sell |
-13,950
| Closed | -$1.36M | – | 940 |
|
|
2021
Q1 | $1.36M | Buy |
13,950
+750
| +6% | +$78.6K | 0.01% | 740 |
|
|
2020
Q4 | $1.26M | Sell |
13,200
-9,622
| -42% | -$929K | 0.01% | 826 |
|
|
2020
Q3 | $2.19M | Buy |
22,822
+4,623
| +25% | +$535K | 0.01% | 753 |
|
|
2020
Q2 | $2.22M | Sell |
18,199
-22,144
| -55% | -$2.45M | 0.01% | 744 |
|
|
2020
Q1 | $3.49M | Buy |
40,343
+23,615
| +141% | +$2.31M | 0.03% | 609 |
|
|
2019
Q4 | $1.8M | Buy |
+16,728
| New | +$1.75M | 0.01% | 823 |
|
|
2014
Q3 | – | Sell |
-124,427
| Closed | -$1.85M | – | 845 |
|
|
2014
Q2 | $1.85M | Buy |
+124,427
| New | +$1.76M | 0.01% | 738 |
|
|
2014
Q1 | – | Sell |
-209,624
| Closed | -$1.96M | – | 820 |
|
|
2013
Q4 | $1.96M | Buy |
209,624
+3,226
| +2% | +$31.5K | 0.02% | 692 |
|
|
2013
Q3 | $2.34M | Buy |
206,398
+1,879
| +0.9% | +$25.8K | 0.02% | 651 |
|
|
2013
Q2 | $2.74M | Buy |
+204,519
| New | +$2.51M | 0.03% | 515 |
|
Other funds holding NBIX
Aviva's NBIX Position: Q2 2026 in Review
Aviva increased its Neurocrine Biosciences (NBIX) stake by 8.4% in Q2 2026, buying an estimated $884K and bringing the position to 77,269 shares worth $13M. The position accounts for 0.02% of the portfolio, ranked #502.
Aviva first reported a position in NBIX in Q2 2013 and has held it in 25 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Aviva held 77,269 shares of Neurocrine Biosciences worth $13M as of Q2 2026.
- Aviva bought 5,959 Neurocrine Biosciences shares in Q2 2026, an estimated $884K.
- Neurocrine Biosciences made up 0.02% of Aviva's portfolio in Q2 2026, its #502 holding.
- Aviva first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 25 quarters since.
- 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.